Janssen-Cilag International’s biologic drug guselkumab (Tremfya) has received approval from the European Commission (EC) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Janssen-Cilag International’s innovator biologic drug guselkumab (Tremfya) has received approval from the European Commission (EC) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Tremfya is the first European Commission-approved biologic that selectively blocks interleukin-23 (IL-23), a cytokine that is a key driver of the immune inflammatory response in psoriasis. The drug is also the only FDA-approved selective IL-23 blocker for the treatment of plaque psoriasis.
Tremfya is a self-injectable treatment that requires 2 starter doses, 1 initially and another 4 weeks later, followed by a maintenance dose every 8 weeks thereafter. Tremfya’s good safety profile, superior head-to-head results compared with Humira (adalimumab) in the VOYAGE 1 and 2 trials, and its mode of action suggest that Tremfya could be a potential competitor to Humira.
The European Commission’s approval of Tremfya, like the earlier approval of the medication by the FDA, was based on data from 3 phase 3 clinical studies:
There were no clear signs of an increased risk of malignancy, major cardiovascular events, or serious infections in patients taking Tremfya.
In September, Janssen announced new, long-term data from the open-label extension of the VOYAGE 1 trial, which further solidified Tremfya’s efficacy:
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Pharmacokinetic Modeling Proposes Cost-Effective Dosing for Adalimumab, Etanercept Biosimilars
October 12th 2024A UK cohort study used drug concentration samples from rheumatoid arthritis patients starting the adalimumab biosimilar Amgevita and the etanercept biosimilar Benepali to simulate drug levels under standard and alternate dosing schedules, suggesting that personalized dosing could reduce costs while potentially increasing efficacy.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.